FDA Grand Rounds: Development and Testing of Warnings for Tobacco Products: Scientific and Regulatory Considerations
January 13, 2022
Virtual
The FDA Grand Rounds is webcast monthly to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.
Warnings inform consumers about risks and are required on many FDA-regulated products. They are especially important for products which have inherent and unavoidable risks associated with their use, such as tobacco products. This presentation will discuss the current regulatory landscape of tobacco product warnings through CTP's authority. We will examine the development and testing of warnings for cigarettes that resulted in the March 2020 final rule "Required Warnings for Cigarette Packages and Advertisements" with a focus on the scientific and regulatory considerations that went into that research and development plan for those warnings.
- Pepper JK, Zarndt AN, Eggers ME, Nonnemaker JM, Portnoy DB. Impact of Pictorial Cigarette Warnings Compared With Surgeon General’s Warnings on Understanding of the Negative Health Consequences of Smoking. Nicotine Tob Res. 2020; 22: 1795-1804.
- Pepper JK, Zarndt AN, Eggers ME, Nonnemaker JM, Portnoy DB. Influence of Warning Statements on Understanding of the Negative Health Consequences of Smoking. Nicotine Tob Res. 2020; 22: 1805-1815.
- Strahan EJ, White K, Fong GT, et al. Enhancing the Effectiveness of Tobacco Package Warning Labels: A Social Psychological Perspective. Tob Control. 2002;11(3):183-190
- Discuss the research conducted at the FDA
- Explain how FDA science impacts public health
- Recognize the scientific and regulatory issues considered by the FDA in developing new cigarette health warnings.
- Discuss the steps in the research process used to develop, test, and refine the new cigarette health warnings.
- Examine the requirements for the new cigarette health warnings final rule and its current status.
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency and external scientific communities.
Lecture 1 January 13, 2022
Time | Topic | Speaker |
---|---|---|
12:00 - 1:00 PM EST | Development and Testing of Warnings for Tobacco Products: Scientific and Regulatory Considerations | David Portnoy, PhD, MPH |
Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Faculty
- Portnoy, David, PhD, MPH, Branch Chief, CTP - nothing to disclose
Planning Committee
- Dinatale, Miriam, DO, Team Leader, Food and Drug Administration - nothing to disclose
- Pfundt, Tiffany, PharmD, Program Coordinator, FDA/CDER/OTBB - nothing to disclose
- Wheelock, Leslie, RN, MS, Director, OSPD, FDA, OC, OCS, OSPD - nothing to disclose
CE Consultation and Accreditation Team
- Bueide, Rachel E., MPhil, Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
All relevant financial relationships have been mitigated.
Registration is complimentary; therefore refunds are not applicable.